CureVac B.V. is a clinical-stage biopharmaceutical company. It engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102. CureVac B.V. is based in Germany.
| Revenue (Most Recent Fiscal Year) | $579.18M |
| Net Income (Most Recent Fiscal Year) | $175.50M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 14.28 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.14 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 5.91 |
| Pre-Tax Margin (Trailing 12 Months) | 232.79% |
| Net Margin (Trailing 12 Months) | 199.92% |
| Return on Equity (Trailing 12 Months) | -23.03% |
| Return on Assets (Trailing 12 Months) | -19.09% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.70 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.69 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.03 |
| Inventory Turnover (Trailing 12 Months) | 8.59 |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.36 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.10 |
| Earnings per Share (Most Recent Fiscal Year) | $0.78 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.72 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 224.34M |
| Free Float | 219.51M |
| Market Capitalization | $1.16B |
| Average Volume (Last 20 Days) | 1.65M |
| Beta (Past 60 Months) | 1.77 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.15% |
| Percentage Held By Institutions (Latest 13F Reports) | 17.26% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |